| Current Price | $15.82 | Mkt Cap | $1.4B |
|---|---|---|---|
| Open | $15.81 | P/E Ratio | 0.00 |
| Prev. Close | $15.79 | Div. (Yield) | $0.00 (0.0%) |
| Daily Range | $15.50 - $15.99 | Volume | 53,812 |
| 52-Wk Range | $4.14 - $22.07 | Avg. Daily Vol. | 1,061,477 |
| Current Price | $15.82 | Mkt Cap | $1.4B |
|---|---|---|---|
| Open | $15.81 | P/E Ratio | 0.00 |
| Prev. Close | $15.79 | Div. (Yield) | $0.00 (0.0%) |
| Daily Range | $15.50 - $15.99 | Volume | 53,812 |
| 52-Wk Range | $4.14 - $22.07 | Avg. Daily Vol. | 1,061,477 |
The best Bull and Bear pitches based on recency and number of recommendations.
Read the most recent pitches from players about MYOV.
Recs
ebadger33
(< 20)
Submitted: 5/7/2020 9:40:57 PM :
Start Price:
$12.88
NYSE:MYOV Score:
+9.47
this stock has seen huge insider interest in buying $11MM. Also moving over the 55 Moving Avg for quite some time. I believe it will keep moving for some time.
Recs
QueenAnneFool
(43.21)
Submitted: 2/7/2019 1:38:36 PM :
Start Price:
$18.55
NYSE:MYOV Score:
-37.21
Smart leadership in a large addressable market.
Recs
dockofthebay
(93.38)
Submitted: 10/13/2017 2:04:46 PM :
Start Price:
$15.15
NYSE:MYOV Score:
-25.14
Myovant Sciences has US rights to Relugolix, intended to relieve pain for woman with uterine fibroids and endometriosis, thanks to a deal with Takeda which has taken Relugolix into Phase 3 trials in Japan with some good results. Relugolix can be taken orally, which is an advantage over drugs which have to be injected to treat uterine fibroids and endometriosis. Myovant's Phase 3 trials of the drug should be complete in late 2018.
Find the members with the highest scoring picks in MYOV.
mrkher (< 20) Score: +161.60
The Score Leader is the player with the highest score across all their picks in MYOV.
|
Top Pick |
Member Name |
Member Rating |
Start Date |
Call |
Time Frame |
Start Price |
Stock Gain |
Index Gain |
Score | Commentary |
|---|---|---|---|---|---|---|---|---|---|---|
| mrkher | < 20 | 11/12/2019 |
|
5Y | $5.89 | +168.59% | +7.00% | +161.60 | 0 Comment | |
| Lienbuster | 96.47 | 6/17/2019 |
|
5Y | $8.95 | +76.76% | +13.88% | +62.88 | 0 Comment | |
| PayrollGeek | < 20 | 6/11/2019 |
|
3Y | $9.21 | +71.77% | +13.57% | +58.20 | 0 Comment | |
| mistermiranga | 99.79 | 6/10/2019 |
|
5Y | $9.33 | +69.56% | +13.96% | +55.60 | 0 Comment | |
| chammond55 | 98.68 | 3/4/2020 |
|
5Y | $10.07 | +57.10% | +7.67% | +49.43 | 0 Comment | |
| bthym | 57.06 | 4/16/2020 |
|
5Y | $10.77 | +46.89% | +18.24% | +28.65 | 0 Comment | |
| BigCaps18 | 36.74 | 7/13/2020 |
|
5Y | $18.50 | -14.49% | +3.09% | +17.58 | 0 Comment | |
| boomtracker | 43.90 | 5/14/2020 |
|
5Y | $11.85 | +33.50% | +18.88% | +14.63 | 0 Comment | |
| janaynay | 79.97 | 1/14/2020 |
|
1Y | $13.79 | +14.72% | +0.61% | +14.11 | 0 Comment | |
| cruisin25 | 30.01 | 4/24/2020 |
|
3M | $12.08 | +30.96% | +17.84% | +13.12 | 0 Comment |
See what the Wall Street professionals think, according to their public statements and filings.
